title: Induction of acquired factor IX inhibitors in cynomolgus monkey (Macaca fascicularis): a new primate model of hemophilia B.
abstract: Inherited hemophilia dog and other transient hemophilic animal models have been used for evaluation of hemostatic agents for use in treatment of hemophilia. We established the first nonhuman primate hemophilic model by immunizing cynomolgus monkeys with human FIX (hFIX) in adjuvants. FIX activities of all three hFIX-immunized monkeys decreased transiently to less than 10% in accordance with prolongation of activated partial thromboplastin time (APTT). Forty micrograms of human factor VIIa (hFVIIa) per kilogram body weight (that was reported to be clinically effective) was administered to the monkey with the highest inhibitor titer to evaluate its usefulness as a hemophilia inhibitor model. Results of thromboelastography (TEG) after the injection demonstrated that the hemostatic effect of FVIIa in this model would be similar to that in hemophiliacs with inhibitors. The antibodies purified from the monkey's plasma by hFIX-immobilized gel were composed of two types: Ca(2+)-dependent and -independent antibodies, with features of IgG(1) and IgG(4). Both types of antibodies reacted to cynomolgus FIX, and only Ca(2+)-dependent antibodies also expressed inhibitory activity against cynomolgus FIX. Immunoblotting analyses of Ca(2+)-dependent antibodies using hFIX and its derivatives suggested that they recognized the Ca(2+)-dependent conformation related to the gamma-carboxyglutamic acid (Gla) domain. Comparison of FIX cDNA from human, cynomolgus monkey, and other species, and the results of immunization of various animals (goats, beagle dogs, rabbits, and rats) with hFIX in adjuvants strongly suggested that the development of acquired FIX inhibitors in the monkeys might be due to high cross-reactivity of the antibodies to molecular mimic antigens, hFIX, and cynomolgus FIX.
authors.affiliation: Kaketsuken (The Chemo-Sero-Therapeutic Research Institute), Kumamoto, Japan. tomokiyo@kaketsuken.or.jp
authors.forename: K
authors.initials: K
authors.lastname: Tomokiyo
authors.forename: K
authors.initials: K
authors.lastname: Teshima
authors.forename: Y
authors.initials: Y
authors.lastname: Nakatomi
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: J
authors.initials: J
authors.lastname: Mizuguchi
authors.forename: C
authors.initials: C
authors.lastname: Nozaki
authors.forename: T
authors.initials: T
authors.lastname: Nakagaki
authors.forename: S
authors.initials: S
authors.lastname: Miyamoto
authors.forename: A
authors.initials: A
authors.lastname: Funatsu
authors.forename: S
authors.initials: S
authors.lastname: Iwanaga
mesh_terms: D000818:Animals; D000910:Antibodies, Heterophile / Q000097:blood; D017931:DNA Primers; D004195:Disease Models, Animal; D004285:Dogs; D005164:Factor IX / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology*; D015942:Factor VIIa / Q000494:pharmacology; D006041:Goats; D002836:Hemophilia B / Q000097:blood*; D006487:Hemostasis; D006801:Humans; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood; D008099:Liver / Q000378:metabolism; D008252:Macaca fascicularis; D010314:Partial Thromboplastin Time; D010976:Platelet Count; D016133:Polymerase Chain Reaction; D011517:Prothrombin Time; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
chemical_list: D000910:Antibodies, Heterophile; D017931:DNA Primers; D007074:Immunoglobulin G; D005164:Factor IX; D015942:Factor VIIa